Raymond James & Associates’s Elicio Therapeutics ELTX Stock Holding History

Raymond James & Associates’s Portfolio ELTX Stock Details ELTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-6,000	Closed	-$34.8K	–	3871
2023 Q1	$34.8K	Hold	6,000	–	–	﹤0.01%	3764
2022 Q4	$48.7K	Hold	6,000	–	–	﹤0.01%	3721
2022 Q3	$55K	Hold	6,000	–	–	﹤0.01%	3697
2022 Q2	$68K	Buy	+6,000	New	+$95.8K	﹤0.01%	3750

Other funds holding ELTX

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MHC

Meyer Handelman Company Rye Brook, New York $3.22B AUM 24.51% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Raymond James & Associates's ELTX Position: Q2 2023 in Review

Raymond James & Associates sold out of Elicio Therapeutics (ELTX) in Q2 2023, closing a stake of 6,000 shares — an estimated $34.8K sold.

Raymond James & Associates first reported a position in ELTX in Q2 2022 and held it in 4 quarters. The position peaked at $68K in Q2 2022. 15 funds tracked by Wall St. Rank hold ELTX as of Q2 2023.

Raymond James & Associates reported no remaining Elicio Therapeutics position as of Q2 2023 after selling out during the quarter.
Raymond James & Associates sold 6,000 Elicio Therapeutics shares in Q2 2023, an estimated $34.8K.
Raymond James & Associates first reported a position in Elicio Therapeutics in Q2 2022 and held it in 4 quarters.
Raymond James & Associates's Elicio Therapeutics position peaked at $68K in Q2 2022.
15 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2023.

Based on Raymond James & Associates's 13F filing for Q2 2023, filed 25 Jul 2023.